Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)
Small Molecules Studied
Download: Excel (XLSX), Comma-separated (CSV), Images (Zip file)
HMS LINCS ID | Name | Alternative Names | LINCS ID | Structure Image | PubChem CID |
---|---|---|---|---|---|
10006-1 | AZD7762 | LSM-1006 | 67077825 | ||
10018-1 | Neratinib | HKI-272 | LSM-42778 | 53398697 | |
10020-1 | Dasatinib | BMS-354825; Sprycel | LSM-1020 | 3062316 | |
10032-1 | Saracatinib | AZD0530 | LSM-1032 | 10302451 | |
10047-1 | Pictilisib | Pictrelisib; GDC-0941; RG-7321 | LSM-1047 | 17755052 | |
10071-1 | Palbociclib | PD0332991 | LSM-1071 | 5330286 | |
10080-1 | Torin2 | LSM-1080 | 51358113 | ||
10102-4 | Taxol | Paclitaxel | LSM-1102 | 441276 | |
10131-1 | Tivantinib | ARQ197 | LSM-1131 | 11494412 | |
10142-1 | Trametinib | GSK-1120212; GSK1120212; GSK1120212B; JTP-74057 | LSM-1143 | 11707110 | |
10144-3 | Olaparib | AZD2281; KU-0059436 | LSM-1145 | 23725625 | |
10147-1 | Buparlisib | BKM120; NVP-BKM120 | LSM-1148 | 16654980 | |
10161-1 | Luminespib | NVP-AUY922 | LSM-1162 | 53401173 | |
10171-1 | TGX221 | LSM-1172 | 9907093 | ||
10179-1 | ABT-737 | LSM-1180 | 11228183 | ||
10194-1 | Cabozantinib | XL-184; BMS-907351 | LSM-1195 | 25102847 | |
10205-1 | INK-128 | MLN0128 | LSM-1206 | 45375953 | |
10233-1 | Alpelisib | BYL719 | LSM-4256 | 56649450 | |
10235-1 | Everolimus | RAD001 | LSM-4258 | 53398658 | |
10245-4 | Cisplatin | CDDP; cis-Diaminodichloroplatinum; Cisplatinum; Lederplatin; Briplatin; Cismaplat | LSM-4268 | ||
10248-3 | Doxorubicin | Adriamycin | LSM-4062 | 31703 | |
10250-3 | Etoposide | LSM-6348 | 36462 | ||
10278-2 | Topotecan | Hycamtin | LSM-5662 | 60700 | |
10282-2 | Vorinostat | suberoylanilide hydroxamic acid (SAHA); Zolinza | LSM-3828 | 5311 | |
10287-2 | Dinaciclib | SCH727965 | LSM-6306 | 46926350 |